EvolveImmune Therapeutics
PrivateLast Round
Strategic
Oct 31, 2024
Total Funding Raised
$92.4M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
EvolveImmune Therapeutics is a biotechnology company developing first-in-class, multi-specific T cell engagers to address unmet needs in oncology and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EvolveImmune Therapeutics Comparables
Compare EvolveImmune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Synthekine | 82% | |
| ITabMed Ltd. | 81% | |
| Crossbow Therapeutics | 80% |
EvolveImmune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Oct 31, 2024 | ||||
| Series A Extension | Dec 13, 2023 | ||||
| Series A | Jan 1, 2020 |
Key People
Founding team and executive leadership
EvolveImmune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Yonjin Capital | Series A |
| Elm Street Ventures | Series A Extension, Series A |
| Solasta Ventures | Series A Extension, Series A |
| Pfizer Ventures | Series A Extension, Series A |
| Takeda Ventures | Series A Extension, Series A |
| Pfizer | Series A Extension |
| Pfizer Ventures | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 38% MoM.
- May 13, 2026
Partnering with Abbvie on pipeline programs.
EvolveImmune Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about EvolveImmune Therapeutics's valuation, stock price, and market status.
Is EvolveImmune a public or private company?
EvolveImmune is a private company.
What is the current stock price of EvolveImmune?
EvolveImmune is a private company with no public stock price. No recent secondary market data is available.
How much is EvolveImmune worth (valuation)?
Valuation information for EvolveImmune is not publicly available.
Can I buy EvolveImmune stock?
EvolveImmune shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was EvolveImmune's last funding round?
EvolveImmune's most recent funding round was Corporate Funding on October 31, 2024.
Who are the main investors in EvolveImmune?
Key investors in EvolveImmune include Yonjin Capital, Solasta Ventures.
Will EvolveImmune IPO soon?
No public IPO plans have been announced for EvolveImmune.
How can I track EvolveImmune secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor EvolveImmune's secondary market activity and sign up for updates.